Indaptus Therapeutics, Inc.

NASDAQ:INDP

Biotechnology

Healthcare
$3.29 -2.21%

-$0.03 today

Market cap
$372.57M
Beta
1.14
P/E (TTM)
-0.2
EPS (TTM)
-$8.70
52W Low $0.92High $8.69

Volume 0.17M

Average 0.97M

INDP Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Indaptus Therapeutics, Inc.NASDAQ: INDP

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $1.67M fell 5.3% year over year, behind the +38.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 68.6% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +29.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.67M-68.6% QoQ
Last fiscal yearDec 2025
$10.49M+29.3% YoY
LTMMar 2026
$10.4M+38.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.3%-100.0%-94.7 pp
1 year+29.3%-100.0%-129.3 pp
3-year CAGR+6.9%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
10.49M USD
Year-over-year change
+29.3%
4-year CAGR
+19.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How INDP compares with its peers on the latest reported figures

  • INDP's LTM Mar 2026 selling, general & admin of $10.4M is the highest of the 2 companies compared; the peer median is $7.25M.
  • Its year-over-year change of +38.2% is the highest of 2, against a peer median of +10.7%.
  • Over three fiscal years its annual growth of +6.9% compares with a peer median of +19.0%.
INDP Competitors Peer median
Selling, General & Admin for INDP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$10.4M +38.2%+6.9%—
AZTRAzitra, Inc.LTM Jun 2026$7.25M +10.7%+19.0%—
Peer median (excluding INDP) $7.25M+10.7%+19.0%—

Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development2.52M6.32M7.62M7.25M9.34M
Selling, General & Admin5.21M8.59M8.76M8.11M10.49M
Operating Expenses7.73M14.91M16.38M15.37M19.83M
Depreciation & Amortization1.4K1.78K1.28K7350
EBITDA(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
EBITDA Margin—————
Operating Income(7.73M)(14.91M)(16.38M)(15.37M)(19.83M)
Operating Margin—————
Interest Income17.72K588.11K000
Interest Expense00000
Other Income / Expenses17.72K588.11K955K343.72K(1.02M)
Income Before Tax(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
Net Margin—————
EPS (Basic)(1.89)(1.73)(1.84)(1.61)(21.58)
EPS (Diluted)(1.89)(1.73)(1.84)(1.61)(21.58)
Weighted Avg Shares4.09M8.26M8.4M9.36M966.12K
Weighted Avg Shares (Diluted)4.09M8.26M8.4M9.36M966.12K

Indaptus Therapeutics, Inc.

NASDAQ:INDP

Intrinsic Alpha fair value

Locked

Current Price

$3.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.